AUTHOR=Chen Yue , Lei Haike , Wang Wei , Zhu Jie , Zeng Chensi , Lu Zhuo , Li Luchun , Li Dairong , Long Bo , Liu Haixia 

TITLE=Characteristics and Predictors of Venous Thromboembolism Among Lymphoma Patients Undergoing Chemotherapy: A Cohort Study in China

JOURNAL=Frontiers in Pharmacology

VOLUME=13

YEAR=2022

URL=https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2022.901887

DOI=10.3389/fphar.2022.901887

ISSN=1663-9812

ABSTRACT=<p><bold>Background:</bold> Venous thromboembolism (VTE) is a potential complication among lymphoma patients. We evaluated the incidence rate and predictors of VTE in lymphoma patients undergoing chemotherapy.</p><p><bold>Methods:</bold> The present study retrospectively studied 1,069 patients with lymphoma who were treated with chemotherapy from 2018 to 2020. We investigated clinical predictors of VTE among all patients. The follow-up results were obtained <italic>via</italic> telephone communication and from inpatient and outpatient records.</p><p><bold>Results:</bold> A total of 1,069 patients underwent chemotherapy for lymphoma. During a mean follow-up of 23.1 months, 52 (4.9%) patients developed VTE. According to a multivariate analysis, the five variables found to be independently associated with VTE were male sex (HR 2.273, 95% CI 1.197–4.316, <italic>p</italic> = 0.012), age &gt;64-years-old (HR 2.256, 95% CI 1.017–5.005, <italic>p</italic> = 0.045), the number of cycles of chemotherapy (HR 4.579, 95% CI 1.173–17.883, <italic>p</italic> = 0.029), platelet count ≥350 × 10<sup>9</sup>/L (HR 2.533, 95% CI 1.187–5.406, <italic>p</italic> = 0.016), and D-dimer &gt;0.5 mg/L (HR 4.367, 95% CI 2.124–8.981, <italic>p</italic> &lt; 0.001).</p><p><bold>Conclusion:</bold> This population-based study confirms the risk factors for VTE among patients with lymphoma who underwent chemotherapy and confirms that targeted thromboprophylaxis may reduce the burden of VTE in this population.</p>